279results about "Suppositories delivery" patented technology

The invention discloses a zinc polyphenol complex suppository as well as a preparation method and application thereof. The preparation process mainly comprises two steps as follows: a, preparation of EGCG-Zn metal polyphenol complex nanoparticles; and b, preparing the nano complex suppository. The method is simple in process, green, environment-friendly and suitable for large-scale preparation. The prepared EGCG-Zn nanoparticles are uniform in particle size and good in stability, and have good antioxidant, anti-inflammatory and tissue repair activity based on a complex network structure formed by self-assembly of EGCG and zinc ions. The nano-particles are firstly treated by adopting a drug pretreatment carrier and then loaded in a suppository matrix to construct a rectal administration type nano-suppository, so that targeted and continuous local drug effect release can be realized. In intervention of radioactive intestinal injury, the suppository not only can relieve oxidative stress and inflammatory response, but also can promote regeneration and repair of intestinal mucosa, and has good treatment potential and clinical application prospect.

The present invention relates to N-palmitoyl ethanolamide for the treatment of inflammatory pain in combination with a non-steroidal anti-inflammatory drug, to the use of N-palmitoyl ethanolamide (referred to as palmitoyl ethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug for the treatment of inflammatory pain. Specifically, the present invention relates to palmitoyl ethanolamide for use in the treatment of inflammatory pain, in particular non-neurological inflammatory pain, in which palmitoyl ethanolamide is administered in combination or in combination with a non-steroidal anti-inflammatory drug as needed, in which the administration is separate, combined or simultaneous.

The present invention relates to the use of N-palmitoylethanolamide (known as palmitoylethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug in the treatment of inflammatory pain. In particular, the present invention is directed to palmitoylethanolamide for use in the treatment of inflammatory pain, in particular non-neuropathic inflammatory pain, where palmitoylethanolamide is administered as needed in association or combination with a non-steroidal anti-inflammatory drug, where said administration is separate, combined, or simultaneous.

The invention relates to a traditional Chinese medicine composition for treating haemorrhoids and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 20-60 parts of sargentgloryvine stem, 15-45 parts of moutan bark, 20-40 parts of dandelion, 20-40 parts of rheum officinale, 20-40 parts of radix paeoniae rubra and 10-30 parts of lithospermum erythrorhizon. The traditional Chinese medicine composition has the effects of cooling blood and detoxifying, promoting blood circulation to remove blood stasis and relieving swelling and pain through combination of all the medicines, can remarkably relieve inflammation and pain of haemorrhoids through test verification, and has the potential of industrial production and popularization.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

The present invention relates to resorcinol derivatives as pharma- ceutically active compounds and methods for their preparation. Resorcinol derivatives have been used to treat a variety of diseases and disorders. Although such treatments are promising, there remains a need in the art for more effective treatments, which is provided by the resorcinol derivatives of the present invention.

The invention discloses a compound musk suppository for promoting blood circulation to remove blood stasis and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine suppository preparation. Comprising the following raw materials in parts by weight: 30-40 parts of mixed traditional Chinese medicine extract dry powder, 60-65 parts of glycerol, 15-20 parts of gelatin, 15-20 parts of water, 15-20 parts of polyethylene glycol and 1.6-2 parts of an emulsifier. According to the compound musk suppository, radix aucklandiae, musk, pericarpium citri reticulatae, semen coicis, radix scutellariae, caulis spatholobi, Japanese peristrophe herb and rhizoma bletillae are used as traditional Chinese medicine efficacy raw materials of mixed traditional Chinese medicine extract dry powder in the compound musk suppository, and then the compound musk suppository is prepared, so that the prepared compound musk suppository has a good promoting effect on the curative effect of haemorrhoids.

The present invention provides use of an MAPK12 inhibitor and a derivative thereof in the preparation of an anti-tumor drug, and particularly relates to the technical field of medicines. The MAPK12 inhibitor (i.e., MIM2) can effectively inhibit the in vitro proliferation ability of colorectal cancer, gastric cancer, pancreatic cancer, and breast cancer cells. MIM2 can effectively inhibit the in vivo proliferation ability of colorectal cancer in NSG mice, and is expected to be used as an anti-tumor small molecule drug in the treatment of colorectal cancer, gastric cancer, pancreatic cancer, breast cancer, and other tumors.

The present invention provides a compound represented by Formula I or its pharmaceutically acceptable salt, stereoisomer, isotopic derivative, solvate (e.g., hydrate), prodrug, metal chelate, crystalline form, or metabolite, and its use in the pharmaceutical field. The above compound, particularly propafenone, can be used to treat and / or prevent psoriasis-related diseases. The present invention also found that, at the same dosage, topical application of the drug is more effective than injection in treating psoriasis-related diseases. The propafenone ointment of the present invention has a superior effect in treating psoriasis-related diseases compared to flecainide ointment, which has a similar antiarrhythmic effect.

Provided herewith are treatment methods and generally therapeutic applications which make use of a composite that comprises a calcium carbonate-containing material, and an associating moiety being associated with said calcium carbonate-containing material.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

Ganoderma lucidum spore oil and its use in preparing anti-cancer-related fatigue medicine. The Ganoderma lucidum spore oil has a triglyceride content of more than 90% and no Ganoderma lucidum triterpenoid compounds are detected. The Ganoderma lucidum spore oil is obtained by supercritical carbon dioxide extraction, eluting with a mixture of petroleum ether and ethyl acetate through a silica gel column, concentrating under reduced pressure, and drying in vacuum. The Ganoderma lucidum spore oil is found to significantly improve fatigue caused by cancer and has good safety, and therefore can be applied to preparing anti-cancer-related fatigue medicine.

This disclosure relates to a multi-component intravaginal ring (IVR) that improves the release of non-hormonal substances, which is useful in multi-purpose preventive techniques (MPT) that simultaneously prevent unplanned pregnancies, prevent or treat sexually transmitted infections (STIs), and optimize vaginal health.

The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an anti-inflammatory analgesic indometacin long-acting suppository and a preparation method thereof.The suppository is composed of indometacin sustained-release microspheres and a modified fatty matrix; eudragit RS100 / RL100 is used as a compound framework of the sustained-release microspheres, the sustained-release microspheres are prepared through a spherocrystal granulation process, the modified fatty matrix is prepared from a mixed fatty glyceride compound matrix sustained-release aid, a three-dimensional suspending dispersant and the like through melting, pre-crystallization and high-speed homogenization processes, and the three-dimensional suspending dispersant contains modified nano silicon dioxide, glycerin monostearate and beewax. According to the invention, a microsphere-matrix dual controlled release system is constructed, so that burst release of drugs is eliminated, and long-acting stable release is realized; the microspheres are prevented from settling and agglomerating through a physical locking mechanism, and the storage stability of the preparation is improved by matching with a dual anti-oxidation system; meanwhile, rectal mucosa stimulation is reduced, the preparation process is simple, the quality is controllable, and the composition is suitable for anti-inflammation and analgesia of various diseases and has a wide clinical application prospect.

One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and / or prevention of a metabolic disorder of an equine animal. For example, the treatment and / or prevention can be for laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and / or Equine Metabolic Syndrome in an equine animal.

The invention provides a semeglutide suppository and a preparation method thereof. The semeglutide suppository provided by the invention is stable in quality and high in bioavailability, and also has the characteristics of rapid drug release and continuous drug administration.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

The present invention relates to the use of N-palmitoylethanolamide (known as palmitoylethanolamide or PEA) in combination with meloxicam in the treatment of inflammatory pain. In particular, the present invention is directed to palmitoylethanolamide for use in the treatment of inflammatory pain, in particular non-neuropathic inflammatory pain, where palmitoylethanolamide is administered in association or combination with meloxicam, where said administration is separate, combined, or simultaneous.

This specification describes a formulation comprising a homogeneous suspension of a biopolymer(s) for drug delivery of an active molecule. In an embodiment, the biopolymer is selected from chitin, chitosan, cellulose, hemicellulose, lignin, amylose, actin, fibrin, collagen, silk, fibroin, keratin, wool, alginic acid, and mixtures thereof. In an embodiment, the biopolymer is mechanically treated with an API under high shear conditions and / or high mechanical energy. The formulation can find particular use in drug delivery systems that involve the transport and release of compounds or molecules for purposes such as pharmaceuticals, drug substances, cosmetics, and the like.

The invention relates to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine extract lotion for treating haemorrhoids and a preparation method of the traditional Chinese medicine extract lotion. The traditional Chinese medicine extracting solution is prepared from the following raw materials in parts by weight: 16-20 parts of garden burnet, 10-12 parts of sophora flowers, 8-10 parts of golden cypress, 8-10 parts of radix sophorae flavescentis, 6-8 parts of fig leaves, 5-8 parts of angelica sinensis and 5-8 parts of fructus kochiae. The preparation method comprises the following steps: crushing and sieving the raw material medicines, adding water, decocting and extracting, combining filtrate, and carrying out vacuum concentration. Through a scientific formula ratio and a synergistic effect of the traditional Chinese medicines, various symptoms such as bleeding, swelling and pain and itching caused by haemorrhoids can be effectively relieved. Moreover, the vacuum concentration process adopted by the invention can be used for concentrating at a relatively low temperature, so that the damage to heat-sensitive effective components is avoided, the stability of the obtained extracting solution is remarkably improved, the final curative effect of the product is ensured, and the problems of slow effect taking and poor stability of medicines in the prior art are solved.

Described is a rectal suppository. The rectal suppository comprises 6-thioguanine, at least one hard fat, and at least one surfactant. Further or alternatively, the rectal suppository comprises about 1 to 9 mg of 6-thioguanine. Further or alternatively, there is described a method of preventing, treating and / or managing inflammatory bowel disease in a subject. The method comprises administering a rectal suppository to the subject in need thereof. Further or alternatively, there is described a method of manufacturing a rectal suppository. The method comprises the steps of (a) heating a hard fat to become a liquid hard fat, (b) adding at least one surfactant to the liquid hard fat, (c) adding 6-thioguanine to the liquid hard fat, (d) forming the hard fat into a rectal suppository. Step (b) is optionally carried out before step (c) or after step (c).

The invention discloses a medical biological dressing suppository matrix and a preparation method thereof, and relates to the technical field of suppositories, the medical biological dressing suppository matrix is prepared by taking gelatin, glycerol, polyethylene glycol derivatives and chitosan quaternary ammonium salt as raw materials, the biocompatibility of the suppository matrix is good, and stimulation and anaphylactic reaction cannot be generated on a medication cavity; and after the suppository matrix is dissolved in the cavity, a film with good adhesion can be formed on the mucous membrane of the cavity, so that the released medicine is fully contacted with the focus for a long time, the curative effect and bioavailability of the medicine are improved, and the suppository is suitable for preparing suppositories for treating gynecological diseases, anorectal diseases and prostate diseases.

The present invention relates to substituted tetrazole derivatives that are useful in the prevention and / or treatment of several medical conditions, including hyperproliferative disorders and diseases.

The invention relates to the technical field of Mongolian medicine preparations, in particular to a coptis chinensis six-ingredient decoction and a preparation method of a suppository of the coptis chinensis six-ingredient decoction. Three heat-clearing and anti-inflammatory Mongolian medicines are added on the basis of a traditional Mongolian medicine coptis chinensis-six-ingredient decoction, the total content of effective components is larger than or equal to 12% through composite enzymolysis, supercritical CO2 extraction and gradient membrane separation and purification, and then stability is enhanced through composite embedding. According to the suppository, a drug carrying system is constructed through a pH-ROS double-response carrier and magnetic targeting, self-healing hydrogel, a temperature-sensitive composite matrix and micro-fluidic spray forming are combined, and storage stability is guaranteed through intelligent packaging. The preparation disclosed by the invention is high in targeting property, capable of being accurately enriched in an intestinal inflammation area, high in mucous membrane adhesive force, long in residence time, convenient and comfortable to take, capable of meeting the melting change time limit, capable of remarkably improving stability and bioavailability, suitable for treating ulcerative colitis and capable of promoting modernization transformation of Mongolian medicine.

Disclosed herein is a device for delivering one or more bioactive agents, the device comprising a first layer comprising a first biodegradable polymer, wherein the first layer has a first and a second side, and wherein a plurality of reservoirs comprising one or more bioactive agents are present on the first side; a second layer comprising a second biodegradable polymer, wherein the second layer is adjacent to the first side of the first layer; and a third layer comprising a third biodegradable polymer, wherein the third layer encapsulates the first and second layers, and wherein at least one face of the device comprises an exposed second layer not coated by the third biodegradable polymer. In one aspect, the first and third biodegradable polymers are poly-ε-caprolactone, while the second biodegradable polymer is a mixture of cellulose acetate phthalate and a poloxamer. Also disclosed are methods for fabricating the devices.

Pharmaceutically acceptable salts of acyclic nucleotide phosphoramidates, and pharmaceutical compositions, morphic forms and dosage forms thereof, for treating HPV and related conditions, including neoplasia.

Disclosed herein are compositions and methods of manufacturing, testing, and using a biocompatible and disposable vaginal suppository, comprising chitosan, collagen, carboxymethyl cellulose, and an enzyme, capable of breaking down vaginal mucous and releasing the active ingredients consistently over extended periods of time. Methods disclosed herein may also include the use of these compositions, methods, and devices for treating vaginal diseases, such as vaginitis, genitourinary syndrome, and other conditions, such as vulvar and vaginal cancer, or cervical cancer.